Jazz Pharma Files 8-K: Routine Update, Nasdaq Listing Confirmed

Ticker: JAZZ · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, compliance

TL;DR

**JAZZ filed a routine 8-K, confirming its Nasdaq listing and non-emerging growth status.**

AI Summary

Jazz Pharmaceuticals plc filed an 8-K on January 8, 2024, to update its registration information, specifically confirming its status as a non-emerging growth company and detailing its ordinary shares are traded on The Nasdaq Stock Market LLC under the symbol JAZZ. This filing is a routine update, indicating the company is adhering to SEC disclosure requirements. For investors, this means Jazz Pharmaceuticals is a well-established company subject to full public company reporting standards, which can be a positive sign of stability and transparency.

Why It Matters

This filing confirms Jazz Pharmaceuticals' compliance with SEC regulations and its established status as a publicly traded company on Nasdaq, providing transparency for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain any information that would indicate a significant change in risk for investors.

Analyst Insight

A smart investor would note this as a routine compliance filing, confirming the company's established public status, and would not base investment decisions solely on this administrative update. It reinforces transparency but offers no new operational or financial insights.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of this 8-K filing by Jazz Pharmaceuticals plc?

This 8-K filing by Jazz Pharmaceuticals plc, dated January 8, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily to update its registration information and confirm its status as a non-emerging growth company.

On which stock exchange are Jazz Pharmaceuticals plc's ordinary shares registered?

Jazz Pharmaceuticals plc's ordinary shares, with a nominal value of $0.0001 per share, are registered on The Nasdaq Stock Market LLC under the trading symbol JAZZ.

What is the company's status regarding being an 'emerging growth company'?

The filing indicates that Jazz Pharmaceuticals plc is NOT an emerging growth company, as defined in Rule 405 of the Securities Act.

What is the company's full legal name and where is its principal executive office located?

The exact name of the registrant is JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY, and its principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7.

What is the Commission File Number for Jazz Pharmaceuticals plc?

The Commission File Number for Jazz Pharmaceuticals plc is 001-33500.

Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-08 07:45:34

Key Financial Figures

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. The January 8, 2024 Jazz Pharmaceuticals plc (the "Company") J.P. Morgan Healthcare Conference corporate overview and financial update presentation includes (i) the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance range for the year ended December 31, 2023, (ii) the Company's expectations that its key growth drivers, Xywav, Epidiolex, and Rylaze, are expected to have combined double-digit percentage revenue growth in 2024, and (iii) the Company's expectations with respect to the growth of high-sodium oxybate authorized generic royalty revenue for the year ended December 31, 2024. A copy of the presentation is attached hereto as Exhibit 99.1. The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Presentation slides by Jazz Pharmaceuticals plc on January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Patricia Carr Name: Patricia Carr Title: Principal Accounting Officer and Interim Principal Financial Officer Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing